References
- Douglas RS, Afifiyan NF, Hwang CJ, et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2010;95(1):430–438. doi:10.1210/jc.2009-1614
- Daumerie C. Epidemiology. In: Wiersinga WM, Kahaly GJ, editors. Graves’ Orbitopathy: A Multidisciplinary Approach Questions and Answers. Basel: Karger; 2010:33–39.
- Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121(3):284–290. doi:10.1016/S0002-9394(14)70276-4
- Kozaki A, Inoue R, Komoto N, et al. Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases. Optom Vis Sci. 2010;87(3):200–204. doi:10.1097/OPX.0b013e3181ce5702
- Dickinson AJ. Clinical manifestations. In: Wiersinga WM, Kahaly GJ, editors. Graves’ Orbitopathy: A Multidisciplinary Approach Questions and Answers. Basel: Karger; 2010:1–25.
- Ponto KA, Pitz S, Pfeiffer N, et al. Quality of life and occupational disability in endocrine orbitopathy. Dtsch Ärztebl Int. 2009;106(17):283–289. doi:10.3238/arztebl.2009.0283
- Terwee CB, Gerding MN, Dekker FW, et al. Development of a disease specific quality of life questionnaire for patients with graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998;82(7):773–779. doi:10.1136/bjo.82.7.773
- Ohnishi T, Noguchi S, Murakami N, et al. Levator palpebrae superioris muscle: MR evaluation of enlargement as a cause of upper eyelid retraction in Graves disease. Radiology. 1993;188(1):115–118. doi:10.1148/radiology.188.1.8511284
- Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375(16):1552–1565. doi:10.1056/NEJMra1510030
- Hiromatsu Y, Sato M, Inoue Y, et al. Localization and clinical significance of thyrotropin receptor mRNA expression in orbital fat and eye muscle tissues from patients with thyroid-associated ophthalmopathy. Thyroid. 1996;6(6):553–562. doi:10.1089/thy.1996.6.553
- Gay AJ, Wolkstein MA. Topical guanethidine therapy for endocrine lid retraction. Arch Ophthalmol. 1966;76(3):364–367. doi:10.1001/archopht.1966.03850010366012
- Shih MJ, Liao SL, Lu HY. A single transcutaneous injectin with Botox for dysthyroid lid retraction. Eye. 2004;18(5):466–469. doi:10.1038/sj.eye.6700690
- Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320–332. doi:10.1210/jc.2010-1962
- Kazim M, Gold KG. A review of surgical techniques to correct upper eyelid retraction associated with thyroid eye disease. Curr Opin Ophthalmol. 2011;22(5):391–393. doi:10.1097/ICU.0b013e3283499433
- Chee E, Chee SP. Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series. Eye. 2008;22(2):311–315. doi:10.1038/sj.eye.6702933
- Lee JM, Lee H, Park M, et al. Subconjunctival injection of triamcinolone for the treatment of upper lid retraction associated with thyroid eye disease. J Craniofac Surg. 2012;23(6):1755–1758. doi:10.1097/SCS.0b013e3182646043
- Xu D, Liu Y, Xu H, et al. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy. Can J Ophthalmol. 2012;47(1):34–41. doi:10.1016/j.jcjo.2011.12.005
- Lee SJ, Rim TH, Jang SY, et al. Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections. Graefes Arch Clin Exp Ophthalmol. 2013;251(1):261–270. doi:10.1007/s00417-012-2153-y
- Kozaki A, Nakamura H, Inoue T. Clinical efficacy of transcutaneous triamcinolone acetonide injection for upper eyelid retraction and swelling in patients with thyroid eye disease. Int Med Case Rep J. 2018;11:325–331. doi:10.2147/IMCRJ.S177671
- Bartalena L, Kahaly GJ, Baldeschi LB, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43–G67. doi:10.1530/EJE-21-0479
- Noh JY, Hamada N, Inoue Y, et al. Thyroid-stimulating antibody is related to graves’ ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves’ disease. Thyroid. 2000;10(9):809–813. doi:10.1089/thy.2000.10.809
- Mukasa K, Yoshimura Noh J, Kouzaki A, et al. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of graves’ ophthalmopathy in untreated Japanese Graves’ disease patients. Endocr J. 2016;63(2):151–157. doi:10.1507/endocrj.EJ15-0137